Friday, October 15, 2021

Spain’s PharmaMar says Covid-19 treatment drug shows clinical efficacy in trials – ET HealthWorld


Spain’s PharmaMar said on Wednesday the first trials of its Aplidin drug on hospitalised patients with moderate Covid-19 showed clinical effects and met safety standards.

The results of these first tests allowed the company to secure Spanish regulatory approval to carry out a late-stage trial on patients in a Phase III trial last month.

“The company has decided to share this data, which demonstrates the therapeutic potential of this drug, with the entire scientific and medical communities, along with patients,” PharmaMar said in a statement.

Britain’s medical regulator authorised the trials two months ago after the journal Science published a paper showing the drug had encouraging antiviral results during vitro testing.

Aplidin is a drug developed by PharmaMar originally to treat cancer but has an effect as an antiviral.

Shares of PharmaMar were up 1% to 80.70 euros ($98.75) in early trading.

Follow and connect with us on , Facebook, Linkedin





Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...